Comparative Pharmacology
Head-to-head clinical analysis: BRONKODYL versus MAXAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKODYL versus MAXAIR.
BRONKODYL vs MAXAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bronkodyl contains theophylline, a xanthine derivative. It acts as a bronchodilator by inhibiting phosphodiesterase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle. Additionally, it blocks adenosine receptors and may have anti-inflammatory effects.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
Theophylline extended-release: 300-600 mg orally every 12 hours; target serum concentration 5-15 mcg/mL.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
None Documented
None Documented
Terminal elimination half-life is 3–8 hours in non-smoking adults, 1–5 hours in smokers, and 20–30 hours in premature neonates; clinical context: half-life increases in hepatic impairment, heart failure, and with certain medications (e.g., cimetidine, fluoroquinolones).
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Renal: approximately 90% as theophylline and its metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid); biliary/fecal: <10%.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Category C
Category C
Bronchodilator
Bronchodilator